Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Verastem's promising therapy for LGSOC could position them as a commercial-stage company by 2025. Click here to find out why ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...

Geode Capital Management LLC increased its position in Verastem, Inc. (NASDAQ:VSTM – Free Report) by 67.6% during the third ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM – Research Report) today and set a price target of $9.00.

RBC Capital raised the firm’s price target on Verastem (VSTM) to $16 from $13 and keeps an Outperform rating on the shares as part of a broader ...

BTIG Research has recently reiterated Verastem Inc (VSTM) stock to Buy rating, as announced on December 31, 2024, according to Finviz. Earlier, on September 30, 2024, Guggenheim had initiated the ...

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.

Highlights,FDA grants Priority Review for new treatment combination in recurrent KRAS mutant LGSOC.,Phase 2 trial results ...

Bionoid Pharma, Inc. ("Bionoid") is pleased to announce the generation of over $100,000 in revenue following the signing of a Binding Letter of Intent (LOI) with Your Supplement Supply Store Ltd.

Cencora, Inc. today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange.